• Login
    View Item 
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2020 RD&E publications
    • View Item
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2020 RD&E publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    The National Lung Matrix Trial of personalized therapy in lung cancer

    Thumbnail
    URI
    https://rde.dspace-express.com/handle/11287/621593
    Author
    Toy, Elizabeth
    Date
    2020-07
    Journal
    Nature
    Type
    Clinical Trial
    Publisher
    Nature Publishing Group
    DOI
    10.1038/s41586-020-2481-8
    Rights
    Copyright © 2020, The Author(s), under exclusive licence to Springer Nature Limited
    Metadata
    Show full item record
    Abstract
    The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against oncogenic drivers that are more prevalent in patients with light exposure to tobacco smoke1-3. As this group represents around 20% of all patients with lung cancer, the discovery of stratified medicine options for tobacco-associated NSCLC is a high priority. Umbrella trials seek to streamline the investigation of genotype-based treatments by screening tumours for multiple genomic alterations and triaging patients to one of several genotype-matched therapeutic agents. Here we report the current outcomes of 19 drug-biomarker cohorts from the ongoing National Lung Matrix Trial, the largest umbrella trial in NSCLC. We use next-generation sequencing to match patients to appropriate targeted therapies on the basis of their tumour genotype. The Bayesian trial design enables outcome data from open cohorts that are still recruiting to be reported alongside data from closed cohorts. Of the 5,467 patients that were screened, 2,007 were molecularly eligible for entry into the trial, and 302 entered the trial to receive genotype-matched therapy-including 14 that re-registered to the trial for a sequential trial drug. Despite pre-clinical data supporting the drug-biomarker combinations, current evidence shows that a limited number of combinations demonstrate clinically relevant benefits, which remain concentrated in patients with lung cancers that are associated with minimal exposure to tobacco smoke.
    Citation
    Middleton G et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020 Jul;583(7818):807-812. doi: 10.1038/s41586-020-2481-8. Epub 2020 Jul 15. Erratum in: Nature. 2020 Sep;585(7826):E21.
    Publisher URL
    https://doi.org/10.1038/s41586-020-2481-8
    Note
    This article is available to RD&E staff via NHS OpenAthens (subject to publisher embargo). Click on the Publisher URL, and log in with NHS OpenAthens if prompted.
    Collections
    • 2020 RD&E publications
    • Cancer Services
    • Oncology

    Browse

    All of RD&E Research RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2021  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV